S&P 500

5.460,62

-0,16%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
PHAXIAM Therapeutics SA (PHXM)
PHAXIAM Therapeutics SA (PHXM) Notícias

PHXM

PHAXIAM Therapeutics (PHXM)

PHAXIAM Therapeutics SA

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:PHXM

1

Data	Hora	Fonte	Título	Código	Companhia
11/03/2024	09:31	Edgar (US Regulatory)	Form 15F-12B - Securities registration termination of foreign private issuers [Section 12(b)]	NASDAQ:PHXM	PHAXIAM Therapeutics SA
11/03/2024	03:00	GlobeNewswire Inc.	PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market	NASDAQ:PHXM	PHAXIAM Therapeutics SA
06/03/2024	02:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:PHXM	PHAXIAM Therapeutics SA
04/03/2024	18:28	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:PHXM	PHAXIAM Therapeutics SA
04/03/2024	18:09	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:PHXM	PHAXIAM Therapeutics SA
21/02/2024	08:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:PHXM	PHAXIAM Therapeutics SA
20/02/2024	18:05	GlobeNewswire Inc.	PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market	NASDAQ:PHXM	PHAXIAM Therapeutics SA
18/01/2024	18:05	GlobeNewswire Inc.	PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024	NASDAQ:PHXM	PHAXIAM Therapeutics SA
14/11/2023	18:05	GlobeNewswire Inc.	PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023	NASDAQ:PHXM	PHAXIAM Therapeutics SA
24/10/2023	17:05	GlobeNewswire Inc.	PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus	NASDAQ:PHXM	PHAXIAM Therapeutics SA
23/10/2023	17:05	GlobeNewswire Inc.	TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation	NASDAQ:PHXM	PHAXIAM Therapeutics SA